Skip To Main Content
Wanlong Tan on Muck Rack

Wanlong Tan

As seen in: Nature, Molecular Cancer
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Wanlong Tan’s profile

Articles by Wanlong Tan

DCST1 drives cisplatin resistance via non-canonical ubiquitination and stabilization of NFAT5 to suppress PANoptosis in bladder cancer

|
By Chun Cao, Zihuan Wang, Yuwen Chen, Qin Fan, Fan Deng, Lina Hou, Zhizhang Wang, Wanlong Tan, Yiqi Lai, Wanteng Ye
| Nature Verified
Abstract Cisplatin-based chemotherapy constitutes the cornerstone of first-line treatment for muscle-invasive and metastatic bladder cancer (BCa); however, the frequent emergence of chemoresistance presents a formidable clinical obstacle. In the present study, by combining a systematic CRISPR-Cas9 E3 ligase library screen with drug sensitivity data from the GDSC database, DCST1 (DC-STAMP Domain Containing 1) was identified as a pivotal driver of cisplatin resistance.
Open in Who Shared Issue with article?

Deep learning-based segmentation and subtype prediction of renal cell carcinoma on contrast-enhanced CT

|
By Xiaoliang Chen, Bihong Xu, Wenbin Guo, Peidan Peng, Zhiyong Zhang, Xiangbo Zeng, Yuanchao Zhu, Jiawei Zhou, Yishan Zhang, Wanlong Tan, Hao Ping, Zaosong Zheng, Yingwei Xie, Zehai Huang, Fengjin Zhao, Gan Mo, Haoxu Wu
| Nature Verified
Abstract Accurate preoperative discrimination of renal cell carcinoma (RCC) subtypes is critical for treatment stratification. We aimed to develop and validate an automated deep learning system for simultaneous tumor segmentation and histopathological subtyping using multicenter contrast-enhanced CT (CECT) imaging. To this end, we constructed a two-stage system comprising separate segmentation and classification models.
Open in Who Shared Issue with article?

CircPPAP2B controls metastasis of clear cell renal cell carcinoma via HNRNPC-dependent alternative splicing and targeting the miR-182-5p/CYP1B1 axis - Molecular Cancer

|
By Xiangbo Zeng, Yuanchao Zhu, Zhiyong Zhang, Qiong Wang, Xiaocen Liu, Chenxi Hu, Tong Wang, Zaosong Zheng, Mengxin Leng, Siying Zeng, Yongyuan Xiao, Shiyu Pang, Bihong Xu, Peidan Peng, Wanlong Tan
| Molecular Cancer Verified
References Capitanio U, Montorsi F. Renal cancer. Lancet. 2016;387:894–906. PubMed Google Scholar Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48. PubMed Google Scholar Powles T. Recent eUpdate to the ESMO Clinical Practice Guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32:422–3.
Open in Who Shared Issue with article?
Show More